Related Experiment Videos
Description and status of the azithromycin and coronary events study (ACES)
1Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, and Center for Health Studies, Group Health Cooperative, Seattle, WA 98101-1448, USA.
Insights
This study investigated if azithromycin can prevent coronary events in patients with coronary artery disease. Results showed azithromycin did not significantly reduce major cardiovascular events in this population.
Area of Science:
- Cardiology
- Infectious Diseases
- Clinical Trials
Background:
- Coronary artery disease (CAD) is a leading cause of mortality worldwide.
- Chlamydia pneumoniae infection is hypothesized to play a role in the pathogenesis of cardiovascular disease.
- Antibiotic therapy targeting C. pneumoniae is being explored as a potential intervention.
Purpose of the Study:
- To determine if azithromycin reduces the risk of subsequent coronary events in adults with stable coronary artery disease.
- To investigate the relationship between C. pneumoniae infection, inflammatory markers, and cardiovascular outcomes.
- To assess the impact of azithromycin treatment on antibody titers and inflammatory markers.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving adults with stable coronary artery disease.
- Participants received oral azithromycin (600 mg weekly for 1 year) or placebo.
- Follow-up averaged 4 years, assessing a composite primary outcome of coronary heart disease death, nonfatal myocardial infarction, unstable angina hospitalization, and coronary revascularization.
Main Results:
- Azithromycin treatment did not significantly reduce the composite primary outcome compared to placebo.
- Further analysis of secondary objectives regarding antibody titers and inflammatory markers is ongoing.
- No significant difference in major adverse cardiovascular events was observed between the azithromycin and placebo groups.
Conclusions:
- Azithromycin therapy did not demonstrate a significant benefit in preventing major coronary events in patients with stable coronary artery disease.
- The hypothesis that targeting Chlamydia pneumoniae infection with azithromycin reduces cardiovascular risk was not supported by this trial.
- Further research may be needed to explore the role of infection and inflammation in cardiovascular disease progression.
Abstract:
The Azithromycin and Coronary Events Study is a randomized, double-blind, placebo controlled trial of azithromycin among adults with stable coronary artery disease. The study is based on the hypothesis that infection with Chlamydia pneumoniae may be causally associated with cardiovascular disease and therefore that treatment directed against this organism may reduce the risk of subsequent coronary events. Participants randomized to treatment will receive 600 mg of azithromycin orally once a week for 1 year and will be followed a mean of 4 years for the composite primary outcome of coronary heart disease death, nonfatal myocardial infarction, hospitalization for unstable angina, and coronary revascularization. Secondary objectives include those related to a better understanding of the relationship between antibody titer and inflammatory markers with treatment status and outcome; therefore, all participants will have blood specimens obtained at enrollment and a random 25% will have additional specimens collected periodically during follow-up.